Janssen announced that the FDA has approved its factor Xa inhibitor rivaroxaban for reduction of risk for major adverse CV events in patients with chronic CAD or peripheral artery disease. Rivaroxaban …
Read Full Story at source (may require registration)
Latest posts by CAD Editor (see all)
- USD/CAD Technical Analysis: 61.8% Fibo. level of the recent upsurge tested ahead of FOMC minutes - February 20, 2019
- USD/CAD – Canadian Dollar In Demand - February 20, 2019
- USD/CAD Forecast: Canadian dollar breaks below 1.32 as greenback under pressure - February 20, 2019